Sirona Biochem eyes commercialization of breakthrough anti-aging compound

TL;DR

Geraldine Dangu, Chief Scientific Officer at Cerona Biocam, discusses their anti-aging discovery and plans to launch a final cosmetic product in 2025.

Transcript

welcome to CEO insights I'm Marilyn De Guzman with Inn I'm speaking with Geraldine dangu Chief scientific officer at cerona biocam hi Geraldine hi pleasure to discuss with you today yes good to see you again so the last time we spoke was in 2023 and you were talking about at that time your anti-aging Discovery just for the purpose of the viewers wh... Read More

Key Insights

• 🛀 Cerona Biocam's anti-aging active, TFC 1326, has shown significant efficacy in improving skin conditions and rejuvenating cells.
• 🚀 The company is strategically pursuing the commercialization of their active ingredient by trademarking it and considering launching a final cosmetic product.
• 💨 By maintaining control over the product launch, Cerona Biocam expects faster revenue generation and increased visibility in the market.
• 😤 The company is building a strong team of experts in formulation, branding, packaging, and clinical trials to ensure a successful product launch.
• 🌱 Cerona Biocam plans to conduct more clinical trials to support cosmetic claims and explore potential future products.
• 🏤 The final product is scheduled to launch in early 2025, focusing on the US, Canadian, and European markets.
• 😱 Cerona Biocam's future plans include expanding their product portfolio to include creams and serums, as well as continuing their work on anticellulite programs.

Questions & Answers

Q: What are the key benefits of Cerona Biocam's anti-aging active, TFC 1326?

TFC 1326 works by protecting and preserving skin cells from external stress, inducing lipid yonic acid and collagen synthesis, and reducing inflammation. It improves skin texture, radiance, decreases wrinkles, and restores cell efficacy.

Q: What has Cerona Biocam done since the initial discovery of TFC 1326?

Cerona Biocam has engaged in discussions with potential partners and explored the option of launching a final cosmetic product. They have taken steps towards trademarking and commercializing their active ingredient, focusing on product development, formulation, branding, packaging, and clinical trials.

Q: Will there be more clinical trials conducted for TFC 1326?

Yes, Cerona Biocam plans to conduct further clinical trials to support their cosmetic claims and evaluate different concentrations of the active ingredient for future products.

Q: What are the launch timelines and target markets for Cerona Biocam's final product?

The product is scheduled to launch in early 2025 as a cure of 21 ampoules for 21 days, aligning with the skin renewal cycle. The initial focus markets will be the US, Canada, and Europe, with a "made in France" and "made in Paris" appeal.

Summary & Key Takeaways

• Cerona Biocam has developed a cosmetic anti-aging active called TFC 1326, which has shown remarkable results in preserving and rejuvenating skin cells.

• The product has undergone safety and efficacy clinical trials, demonstrating significant improvements in skin texture, radiance, wrinkle reduction, and skin laxity.

• Cerona Biocam is now focusing on the commercialization of their active ingredient, including trademarking it and taking steps towards launching a final cosmetic product.